Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of North Carolina, Chapel Hill, North Carolina.
Thyroid. 2020 Sep;30(9):1297-1305. doi: 10.1089/thy.2019.0652. Epub 2020 Apr 16.
Despite the excellent survival of most patients with differentiated thyroid cancer (DTC), recurrent and persistent disease remain major concerns for physicians and patients. However, studies on patient report of recurrent and persistent disease are lacking. Between February 1, 2017, and October 31, 2018, we surveyed eligible patients who were diagnosed with DTC between 2014 and 2015 from the Georgia and Los Angeles Surveillance, Epidemiology, and End Results cancer registries ( = 2632; response rate, 63%). Patients who reported current disease status were included in this study ( = 2454). Patient-reported data were linked to registry data. A multivariable, multinomial logistic regression analysis was conducted to determine patient and tumor characteristics associated with recurrent and persistent thyroid cancer. Quality of life was evaluated using the Patient-Reported Outcomes Measurement Information System-Global Health v1.2 questionnaire. Meaningful change in global health was defined as a minimal difference of a half standard deviation or 5 points compared with the mean ( score = 50) of a sample population matching the United States 2000 General Census. Of the 2454 patients completing the survey, 95 (4.1%) reported recurrent disease and 137 (5.8%) reported persistent disease. In multinomial analyses, T3/T4 classification and cervical lymph node involvement (N1) were associated with both report of recurrent (adjusted relative risk ratio [RRR] 1.99, 95% confidence interval [CI 1.16-3.42]; adjusted RRR 2.03 [CI 1.29-3.21], respectively) and persistent disease (adjusted RRR 3.48 [CI 1.96-6.20]; adjusted RRR 3.56 [CI 2.41-5.24], respectively). Additionally, Hispanic ethnicity was associated with report of recurrent disease (adjusted RRR 1.99 [CI 1.23-3.24]). Regarding quality of life, the median scores in patients with persistent disease met criteria for meaningful change in global physical health (-score = 44.9) and global mental health (-score = 43.5) when compared with the general population norms. Median scores in patients with cured or recurrent disease did not meet criteria for meaningful change. Patient report is a reasonable method of assessing recurrent and persistent disease. Impact on quality of life is more marked for patients with reported persistent disease. Our findings will help personalize treatment and long-term follow-up in these patients.
尽管大多数分化型甲状腺癌(DTC)患者的生存情况良好,但疾病的复发和持续仍是医生和患者关注的主要问题。然而,目前缺乏关于患者对复发和持续疾病报告的研究。 本研究于 2017 年 2 月 1 日至 2018 年 10 月 31 日期间,对 2014 年至 2015 年间在佐治亚州和洛杉矶监测、流行病学和最终结果癌症登记处( = 2632;应答率为 63%)诊断为 DTC 的合格患者进行了调查。包括报告当前疾病状态的患者( = 2454)。将患者报告的数据与登记处的数据进行了关联。采用多变量多项逻辑回归分析确定与复发性和持续性甲状腺癌相关的患者和肿瘤特征。使用患者报告的结局测量信息系统-全球健康 v1.2 问卷评估生活质量。全球健康方面的有意义变化定义为与匹配美国 2000 年一般人口普查的样本人群平均值(得分 = 50)相比,半标准差或 5 分的最小差异。在完成调查的 2454 名患者中,95 名(4.1%)报告了疾病复发,137 名(5.8%)报告了疾病持续存在。在多项分析中,T3/T4 分类和颈部淋巴结受累(N1)与报告的复发(调整后的相对风险比 [RRR] 1.99,95%置信区间 [CI 1.16-3.42];调整后的 RRR 2.03 [CI 1.29-3.21])和持续性疾病(调整后的 RRR 3.48 [CI 1.96-6.20];调整后的 RRR 3.56 [CI 2.41-5.24])均相关。此外,西班牙裔与报告的疾病复发相关(调整后的 RRR 1.99 [CI 1.23-3.24])。关于生活质量,与一般人群的标准相比,持续性疾病患者的中位数评分符合全球身体健康(-评分 = 44.9)和全球心理健康(-评分 = 43.5)有意义变化的标准。治愈或复发疾病患者的中位数评分不符合有意义变化的标准。患者报告是评估复发性和持续性疾病的合理方法。报告持续性疾病对生活质量的影响更为显著。我们的发现将有助于为这些患者提供个性化的治疗和长期随访。